Application of a fluorescence-based continuous-flow bioassay to screen for diversity of cytochrome P450 BM3 mutant libraries

Journal of Biomolecular Screening

Volumn 16, Issue 2, 2011, Pages 239-250

  Reinen, Jelle ^a   Ferman, Suilan ^a   Vottero, Eduardo ^a   Vermeulen, Nico P E ^a   Commandeur, Jan N M ^a  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

BM3 affinity profiling; continuous flow enzyme affinity detection (EAD); cytochrome P450 monooxygenase BM3 (P450 BM3); flow injection analysis (FIA)

Indexed keywords

AMITRIPTYLINE; ARIPIPRAZOLE; BUSPIRONE; CYTOCHROME P450 BM3; DEXTROMETHORPHAN; DULOXETINE; HEXESTROL; IMATINIB; KETOCONAZOLE; MUTANT PROTEIN; NIFEDIPINE; NORETHISTERONE; OMEPRAZOLE; PAROXETINE; RESORUFIN; RESVERATROL; ROSIGLITAZONE; TRAMADOL;

ARTICLE; BIOASSAY; CONTINUOUS FLOW ENZYME AFFINITY DETECTION; DEALKYLATION; DRUG METABOLISM; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME KINETICS; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME SUBSTRATE; FLOW INJECTION ANALYSIS; FLUORESCENCE ANALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MOLECULAR LIBRARY; PRIORITY JOURNAL; PROTEIN SYNTHESIS; REACTION TIME; SCREENING;

BUSPIRONE; COENZYMES; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME ASSAYS; FLOW INJECTION ANALYSIS; FLUORESCENCE; GENE LIBRARY; GENETIC VARIATION; KINETICS; MUTANT PROTEINS; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, FLUORESCENCE; SUBSTRATE SPECIFICITY;

EID: 79951963841     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057110394180     Document Type: Article

References (38)

1. Denisov IG, Makris TM, Sligar SG, Schlichting I.: Structure and chemistry of cytochrome P450. Chem Rev 2005 ; 105: 2253-2277. (Pubitemid 40951784)
2. Goeptar AR, Scheerens H., Vermeulen NP: Oxygen and xenobiotic reductase activities of cytochrome P450. Crit Rev Toxicol 1995 ; 25: 25-65.
3. Guengerich FP: Reactions and significance of cytochrome P-450 enzymes. J Biol Chem 1991 ; 266: 10019-10022.
4. Chefson A., Auclair K.: Progress towards the easier use of P450 enzymes. Mol Biosyst 2006 ; 2: 462-469. (Pubitemid 44433803)
5. Alavijeh MS, Palmer AM: The pivotal role of drug metabolism and pharmacokinetics in the discovery and development of new medicines. IDrugs 2004 ; 7: 755-763.
6. Fura A., Shu YZ, Zhu M., Hanson RL, Roongta V., Humphreys WG: Discovering drugs through biological transformation: role of pharmacologically active metabolites in drug discovery. J Med Chem 2004 ; 47: 4339-4351. (Pubitemid 39096823)
7. Munro AW, Leys DG, McLean KJ, Marshall KR, Ost TW, Daff S.,, et al. P450 BM3: the very model of a modern flavocytochrome. Trends Biochem Sci 2002 ; 27: 250-257. (Pubitemid 34655446)
8. Narhi LO, Fulco AJ: Identification and characterization of two functional domains in cytochrome P-450BM-3, a catalytically self-sufficient monooxygenase induced by barbiturates in Bacillus megaterium. J Biol Chem 1987 ; 262: 6683-6690.
9. Carmichael AB, Wong LL: Protein engineering of Bacillus megaterium CYP102: the oxidation of polycyclic aromatic hydrocarbons. Eur J Biochem 2001 ; 268: 3117-3125. (Pubitemid 32862999)
10. Dietrich M., Do TA, Schmid RD, Pleiss J., Urlacher VB: Altering the regioselectivity of the subterminal fatty acid hydroxylase P450 BM-3 towards gamma- and delta-positions. J Biotechnol 2009 ; 139: 115-117.
11. Seifert A., Vomund S., Grohmann K., Kriening S., Urlacher VB, Laschat S.,, et al. Rational design of a minimal and highly enriched CYP102A1 mutant library with improved regio-, stereo- and chemoselectivity. Chembiochem 2009 ; 10: 853-861.
12. Munzer DF, Meinhold P., Peters MW, Feichtenhofer S., Griengl H., Arnold FH,, et al. Stereoselective hydroxylation of an achiral cyclopentanecarboxylic acid derivative using engineered P450s BM-3. Chem Commun (Camb) 2005 ; 2597-2599. (Pubitemid 40825256)
13. Damsten MC, van Vugt-Lussenburg BM, Zeldenthuis T., de Vlieger JS, Commandeur JN, Vermeulen NP: Application of drug metabolising mutants of cytochrome P450 BM3 (CYP102A1) as biocatalysts for the generation of reactive metabolites. Chem Biol Interact 2008 ; 171: 96-107. (Pubitemid 350191849)
14. Damsten MC, de Vlieger JS, Niessen WM, Irth H., Vermeulen NP, Commandeur JN: Trimethoprim: novel reactive intermediates and bioactivation pathways by cytochrome p450s. Chem Res Toxicol 2008 ; 21: 2181-2187.
15. Kim DH, Kim KH, Kim DH, Liu KH, Jung HC, Pan JG,, et al. Generation of human metabolites of 7-ethoxycoumarin by bacterial cytochrome P450 BM3. Drug Metab Dispos 2008 ; 36: 2166-2170.
16. Kim DH, Ahn T., Jung HC, Pan JG, Yun CH: Generation of the human metabolite piceatannol from the anticancer-preventive agent resveratrol by bacterial cytochrome P450 BM3. Drug Metab Dispos 2009 ; 37: 932-936.
17. Landwehr M., Hochrein L., Otey CR, Kasrayan A., Backvall JE, Arnold FH: Enantioselective alpha-hydroxylation of 2-arylacetic acid derivatives and buspirone catalyzed by engineered cytochrome P450 BM-3. J Am Chem Soc 2006 ; 128: 6058-6059.
18. Sawayama AM, Chen MM, Kulanthaivel P., Kuo MS, Hemmerle H., Arnold FH: A panel of cytochrome P450 BM3 variants to produce drug metabolites and diversify lead compounds. Chemistry 2009 ; 15: 11723-11729.
19. Peters MW, Meinhold P., Glieder A., Arnold FH: Regio- and enantioselective alkane hydroxylation with engineered cytochromes P450 BM-3. J Am Chem Soc 2003 ; 125: 13442-13450. (Pubitemid 37352128)
20. Wong TS, Wu N., Roccatano D., Zacharias M., Schwaneberg U.: Sensitive assay for laboratory evolution of hydroxylases toward aromatic and heterocyclic compounds. J Biomol Screen 2005 ; 10: 246-252. (Pubitemid 40617162)
21. Alcalde M., Farinas ET, Arnold FH: Colorimetric high-throughput assay for alkene epoxidation catalyzed by cytochrome P450 BM-3 variant 139-3. J Biomol Screen 2004 ; 9: 141-146.
22. Tsotsou GE, Cass AE, Gilardi G.: High throughput assay for cytochrome P450 BM3 for screening libraries of substrates and combinatorial mutants. Biosens Bioelectron 2002 ; 17: 119-131. (Pubitemid 34003618)
23. Li QS, Schwaneberg U., Fischer P., Schmid RD: Directed evolution of the fatty-acid hydroxylase P450 BM-3 into an indole-hydroxylating catalyst. Chemistry 2000 ; 6: 1531-1536.
24. Schwaneberg U., Schmidt-Dannert C., Schmitt J., Schmid RD: A continuous spectrophotometric assay for P450 BM-3, a fatty acid hydroxylating enzyme, and its mutant F87A. Anal Biochem 1999 ; 269: 359-366. (Pubitemid 29201037)
25. Estabrook RW, Faulkner KM, Shet MS, Fisher CW: Application of electrochemistry for P450-catalyzed reactions. Methods Enzymol 1996 ; 272: 44-51. (Pubitemid 26299866)
26. Lussenburg BM, Babel LC, Vermeulen NP, Commandeur JN: Evaluation of alkoxyresorufins as fluorescent substrates for cytochrome P450 BM3 and site-directed mutants. Anal Biochem 2005 ; 341: 148-155. (Pubitemid 40615731)
27. Burke MD, Thompson S., Weaver RJ, Wolf CR, Mayer RT: Cytochrome P450 specificities of alkoxyresorufin O-dealkylation in human and rat liver. Biochem Pharmacol 1994 ; 48: 923-936. (Pubitemid 24285170)
28. van Vugt-Lussenburg BM, Stjernschantz E., Lastdrager J., Oostenbrink C., Vermeulen NP, Commandeur JN: Identification of critical residues in novel drug metabolizing mutants of cytochrome P450 BM3 using random mutagenesis. J Med Chem 2007 ; 50: 455-461. (Pubitemid 46239780)
29. Kool J., van Liempd SM, Ramautar R., Schenk T., Meerman JH, Irth H.,, et al. Development of a novel cytochrome p450 bioaffinity detection system coupled online to gradient reversed-phase high-performance liquid chromatography. J Biomol Screen 2005 ; 10: 427-436. (Pubitemid 41233221)
30. Kool J., van Liempd SM, Harmsen S., Beckman J., van Elswijk D., Commandeur JN,, et al. Cytochrome P450 bio-affinity detection coupled to gradient HPLC: on-line screening of affinities to cytochrome P4501A2 and 2D6. J Chromatogr B Analyt Technol Biomed Life Sci 2007 ; 858: 49-58. (Pubitemid 47513596)
31. Kool J., van Liempd SM, van Rossum H., van Elswijk DA, Irth H., Commandeur JN,, et al. Development of three parallel cytochrome P450 enzyme affinity detection systems coupled on-line to gradient high-performance liquid chromatography. Drug Metab Dispos 2007 ; 35: 640-648. (Pubitemid 46513268)
32. Burke MD, Mayer RT: Differential effects of phenobarbitone and 3-methylcholanthrene induction on the hepatic microsomal metabolism and cytochrome P-450-binding of phenoxazone and a homologous series of its n-alkyl ethers (alkoxyresorufins). Chem Biol Interact 1983 ; 45: 243-258. (Pubitemid 13039225)
33. Maurer SC, Schulze H., Schmid RD, Urlacher V.: Immobilisation of P450 BM-3 and an NADP+ cofactor recycling system: towards a technical application of heme-containing monooxygenases in fine chemical synthesis. Adv Synth Catal 2003 ; 345: 802-810. (Pubitemid 37393167)
34. Vottero E., Rea V., Lastdrager J. Honing M. Vermeulen NP, Commandeur JN: Role of residue 87 in substrate and regioselectivity of drug metabolizing cytochrome P450 CYP102A1 M11. Manuscript submitted.
35. Tartof KD, Hobbs CA: New cloning vectors and techniques for easy and rapid restriction mapping. Gene 1988 ; 67: 169-182.
36. de Vlieger JS, Kolkman AJ, Ampt KA, Commandeur JN, Vermeulen NP, Kool J.,, et al. Determination and identification of estrogenic compounds generated with biosynthetic enzymes using hyphenated screening assays, high resolution mass spectrometry and off-line NMR. J Chromatogr B Analyt Technol Biomed Life Sci 2010 ; 878: 667-674.
37. Zhu M., Zhao W., Jimenez H., Zhang D., Yeola S., Dai R.,, et al. Cytochrome P450 3A-mediated metabolism of buspirone in human liver microsomes. Drug Metab Dispos 2005 ; 33: 500-507. (Pubitemid 40393192)
38. Fandino AS, Nagele E., Perkins PD: Automated software-guided identification of new buspirone metabolites using capillary LC coupled to ion trap and TOF mass spectrometry. J Mass Spectrom 2006 ; 41: 248-255. (Pubitemid 43260166)